Bolt acquires Prana in reverse merger, backed by $120M placement
What's the deal? Bolt Biotherapeutics has acquired clinical-stage biotech Prana Therapies in a stock-for-stock reverse merger, paired with a $120 million private placement. The combined company will focus on advancing PRA-216, Prana's lead drug candidate for inflammatory diseases.
The terms: The financing brings $120 million in upfront gross proceeds, with up to $60 million more available if accompanying warrants are exercised. Investors include Deep Track CapitalDealroom has a profile for this one. Try Dealroom →, ADAR1 Capital, Andreessen Horowitz, and Casdin Capital.
What changes? Prana shareholders and the new investors will own most of the combined company; Bolt's legacy shareholders retain about 6.9% on an as-converted basis. Sheila Gujrathi, Prana's co-founder and former chief executive, joins Bolt's board and becomes chief strategy officer.
What's the endgame? PRA-216 is a bispecific antibody targeting IL-4Rα and TSLP, designed for infrequent, at-home dosing. It is in Phase 2 trials for asthma, COPD, and atopic dermatitis, with a study in eosinophilic esophagitis planned. The proceeds are expected to fund operations into 2028.
What could go wrong? The drug's value proposition remains unproven in patients. Phase 1 results in healthy volunteers showed biomarker activity and extended exposure, but patient data across all four indications isn't expected until the second quarter of 2027.
The signal: The deal is a well-funded bet on a differentiated, long-acting antibody strategy rather than evidence the drug beats established treatments. It lands amid continued investor appetite for select clinical-stage assets — fellow inflammation biotech First TracksDealroom has a profile for this one. Try Dealroom → announced a $200 million private placement earlier this month.
Read more: smb.magnoliastatelive.com
Image credit: Generated with Gemini
